PUMA BIOTECHNOLOGY, INC.

Listed Company

PBYICIK 0001401667NasdaqAcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$228.37M

Net Income

$31.10M

Total Assets

$216.30M

Equity

$130.34M

Shares Out

50.90M

Op. Cash Flow

$41.80M

PBYI$8.53+153.72% · past yearDBEQ Basic

Daily closing prices

Business

Puma Biotechnology is a biopharmaceutical company that develops and commercializes innovative cancer therapies. The company's lead product is NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for HER2-positive breast cancer in extended adjuvant and metastatic settings. Puma also holds worldwide rights to alisertib, an Aurora Kinase A inhibitor in clinical development for small cell lung cancer and hormone receptor-positive breast cancer. The company commercializes NERLYNX through a direct specialty sales force in the United States and through exclusive sub-license agreements with regional partners in over 40 countries internationally.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	228	230	236	228	253
Cost of sales	58	64	63	55	64
Selling, general and administrative	71	80	90	90	116
Research and development	62	55	50	52	72
Total operating costs and expenses	191	200	203	204	252
Income from operations	37	31	33	24	1
Interest income	4	5	3	813,000	160,000
Interest expense	−7	−12	−13	−12	—
Other income	1	862,000	759,000	−28,000	292,000
Total other expenses, net	−2	−7	−10	−23	−30
Income Before Income Taxes	36	24	23	457,000	−29
Current income tax (expense)	−1	−897,000	−1	−455,000	—
Deferred income tax (expense) benefit	−3	7	0	0	—
Net income	31	30	22	2,000	−29
Net income per share of common stockbasic (in dollars per share)	0.62	0.62	0.46	0	−0.72
Net income per share of common stockdiluted (in dollars per share)	0.61	0.62	0.45	0	−0.72
Weighted-average shares of common stock outstandingbasic (in shares)	50	49	47	45	41
Weighted-average shares of common stock outstandingdiluted (in shares)	51	49	48	45	41

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	30	69	85	76	63
Marketable securities	68	32	11	5	19
Accounts receivable, net of allowance for credit loss of $0 and $362	54	32	48	40	33
Inventory	6	9	7	5	7
Prepaid expenses, current	4	6	4	6	9
Restricted cash, current	2	0	—	0	9
Other assets, current	256,000	91,000	912,000	2	447,000
Total current assets	163	148	156	134	140
Lease right-of-use assets, net	5	5	8	11	14
Property and equipment, net	187,000	515,000	855,000	1	2
Intangible assets, net	41	51	61	71	66
Restricted cash, long-term	0	2	2	3	3
Deferred tax assets	4	7	0	—	—
Prepaid expenses and other, long-term	3	284,000	3	2	1
Total assets	216	213	231	222	227
Accounts payable	5	6	7	6	11
Accrued expenses, current	50	37	53	53	93
Lease liabilities, current	1	6	5	4	4
Post-marketing commitment liability	2	3	975,000	1	2
Current portion of long-term debt	23	45	34	0	0
Other liabilities, current	142,000	0	—	—	—
Total current liabilities	81	96	99	77	110
Lease liabilities, long-term	5	1	7	12	16
Post-marketing commitment liability, long-term	0	2	5	5	5
Total long-term debt, net	0	22	66	98	97
Other liabilities, long-term	0	121,000	121,000	—	—
Total liabilities	86	121	177	200	229
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock - $.0001 par value per share; 100,000,000 shares authorized; 50,408,023 shares issued and outstanding at December 31, 2025 and 49,105,834 issued and outstanding at December 31, 2024	5,000	5,000	5,000	5,000	4,000
Additional paid-in capital	1,414	1,407	1,399	1,388	1,364
Accumulated other comprehensive income	36,000	6,000	−4,000	0	−2,000
Accumulated deficit	−1,284	−1,315	−1,345	−1,367	−1,367
Total stockholders equity	130	92	53	22	−2
Total liabilities and stockholders equity	216	213	231	222	227

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	11	12	12	10	11
Stock-based compensation	7	8	10	12	33
Provision for credit loss recovery	−400,000	−500,000	900,000	0	−1
Loss on disposal of property and equipment	4,000	0	0	1,000	1,000
Loss on impairment of asset	0	0	625,000	0	0
Accounts receivable, net	−21	16	−8	−8	−6
Inventory, net	3	−2	−3	3	−4
Prepaid expenses and other	−325,000	1	820,000	2	3
Other current assets	−165,000	821,000	2	−2	3
Accounts payable	−453,000	−1	449,000	−5	−902,000
Operating lease assets and liabilities, net	−2	−2	−1	−920,000	−707,000
Accrued expenses and other	13	−16	−8	−33	5
Post-marketing commitment liability	−2	−1	−940,000	−921,000	−1
Net cash provided by operating activities	42	39	27	−16	21
Purchase of property and equipment	−71,000	−56,000	−140,000	0	0
Purchase of available-for-sale securities	−108	−76	−24	−5	−38
Maturity of available-for-sale securities	72	56	17	19	27
Purchase of intangible assets	0	0	−13	0	0
Net cash used in investing activities	−36	−20	−19	7	−11
Net proceeds from shares issued under employee stock plans	130,000	150,000	0	0	—
Payment of debt	−44	−33	0	0	−100
Payment of exit costs	−888,000	−666,000	0	0	—
Net cash used in financing activities	−45	−34	0	12	−32
Net (decrease) increase in cash, cash equivalents and restricted cash	−40	−15	8	4	−22
Property and equipment purchases in accounts payable	5,000	0	26,000	0	0
Interest paid	6	11	12	10	10
Income taxes paid	2	1	737,000	384,000	324,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is PUMA BIOTECHNOLOGY, INC.'s CIK number?

PUMA BIOTECHNOLOGY, INC.'s SEC CIK number is 0001401667 (1401667). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find PUMA BIOTECHNOLOGY, INC.'s SEC filings?

All of PUMA BIOTECHNOLOGY, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did PUMA BIOTECHNOLOGY, INC. last report earnings?

PUMA BIOTECHNOLOGY, INC. (PBYI) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-015621). This is PUMA BIOTECHNOLOGY, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is PUMA BIOTECHNOLOGY, INC.'s most recent earnings 8-K?

PUMA BIOTECHNOLOGY, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001437749-26-015621. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View PUMA BIOTECHNOLOGY, INC.'s latest earnings 8-K →
Look up any company's CIK number →